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Background. The continuum of care is at the forefront of the domestic human immunodeficiency virus (HIV) agen-
da, with the Institute of Medicine (IOM) and Department of Health and Human Services (DHHS) recently releasing
clinical core indicators. Core indicators for retention in care are calculated based on attended HIV care clinic visits. Beyond
these retention core indicators, we evaluated the additional prognostic value of missed clinic visits for all-cause mortality.
Methods. We conducted a multisite cohort study of 3672 antiretroviral-naive patients initiating antiretroviral ther-
apy (ART) during 2000–2010. Retention in care was measured by the IOM and DHHS core indicators (2 attended visits
at defined intervals per 12-month period), and also as a count of missed primary HIV care visits (no show) during a 24-
monthmeasurement period following ART initiation. All-cause mortality was ascertained by query of the Social Security
Death Index and/or National Death Index, with adjusted survival analyses starting at 24 months after ART initiation.
Results. Among participants, 64% and 59% met the IOM and DHHS retention core indicators, respectively, at 24
months. Subsequently, 332 patients died during 16 102 person-years of follow-up. Failure to achieve the IOM and
DHHS indicators through 24 months following ART initiation increased mortality (hazard ratio [HR] = 2.23; 95% con-
fidence interval [CI], 1.79–2.80 andHR = 2.36; 95% CI, 1.89–2.96, respectively). Among patients classified as retained by
the IOM or DHHS clinical core indicators, >2 missed visits further increased mortality risk (HR = 3.61; 95% CI, 2.35–
5.55 and HR = 3.62; 95% CI, 2.30–5.68, respectively).
Conclusions. Beyond HIV retention core indicators, missed clinic visits were independently associated with all-
cause mortality. Caution is warranted in relying solely upon retention in care core indicators for policy, clinical, and
programmatic purposes.
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In recent years, considerable attention has focused on
the importance of engagement in human immunodefi-
ciency virus (HIV) medical care in contributing to
individual and public health outcomes. The HIV care
continuum (“treatment cascade”) has become the sen-
tinel image depicting the domestic HIV epidemic across
a sequence of steps including acquisition of HIV infec-
tion, HIV diagnosis, linkage to medical care, retention
in medical care, antiretroviral therapy (ART) receipt,
and plasma viral suppression (<200 copies/mL) [1–4].
Of the estimated 1.2 million people living with HIV in-
fection in the United States, only 25% have achieved
plasma viral suppression, with dramatic drop-offs in
linkage and retention in medical care representing the
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most prominent barriers to achieving this vital surrogate marker
of effective treatment. Research has clearly shown that achieving
and sustaining plasma viral suppression is associated with a de-
creased frequency of clinical events, includingmortality, and with
dramatic reductions in HIV transmission [5–7]. However, more
than half of persons diagnosed with HIV infection in the United
States are not engaged in ongoing medical care [8],making reten-
tion in care the greatest barrier to fully achieving the individual
and population health benefits afforded by viral suppression [9,
10]. Accordingly, the US National HIV/AIDS Strategy and HIV
Care Continuum Initiative, recently released by executive order,
place considerable focus on HIV care engagement as a critical
component to achieving the overarching goals of reducing new
HIV infections, improving health outcomes for people living
with HIV, and reducing HIV-related health disparities [11, 12].
In response to these initiatives, the Institute of Medicine (IOM)
and the US Department of Health and Human Services (DHHS)
have put forth clinical core indicators, including measures for re-
tention in HIV care, which now serve as national benchmarks,
with reporting on these indicators required by agencies receiving
federal funding for the provision of HIV services [13, 14].
Although hundreds of trials have comparatively evaluated
ART regimens over the past 2 decades, there is a paucity of rig-
orous scientific research that has been conducted on the early
steps of the HIV care continuum [15]. In particular, studies on
engagement in care including initial linkage, subsequent reten-
tion, and reengagement in medical care among those who drop
out are limited, but rapidly emerging in the literature. As a na-
scent field, a number of approaches have been developed to
quantify and measure retention in care, with no clear gold stan-
dard established [16, 17]. In broad terms, retention measures in-
clude both those based solely on attended clinic visits and others
that account for missed (no-show) clinic visits. Recent research
indicates that these 2 approaches to quantification (attended vs
missed) may tap into different aspects of HIV care retention
[16]. To date, most studies have utilized single retention mea-
sures in isolation, and have not evaluated the added value of
using multiple measures concomitantly or sequentially. We eval-
uated the association of missed clinic visits for all-cause mortality
when used in conjunction with the IOM and DHHS clinical in-
dicators of retention in care, both of which are calculated based
solely upon attended visits. We hypothesized that beyond the re-
tention in care classification according to these core indicators
(retained vs not retained), missed clinic visits would have inde-
pendent and substantial associations with all-cause mortality.
METHODS
Design Overview
We conducted an analysis of systematically captured data from
a multisite HIV clinical cohort collaboration, the Centers for
AIDS Research (CFAR) Network of Integrated Clinical Systems
(CNICS).
Setting and Participants
CNICS is a nationally distributed HIV clinical cohort that has
been described in detail previously [18]. In brief, the CNICS co-
hort includes >28 000 HIV-infected adults (contributing
>125 000 person-years of follow-up, on average 4.5 years per
patient) who have received HIV care at 1 of 8 CFAR sites, dating
back to 1995. Every 3 months, sites transmit comprehensive and
well-defined data elements captured from point-of-care elec-
tronic health record systems using standardized terminology
and format. Systematic and rigorous processes for data verifica-
tion and quality assurance are in place to generate a centralized
high-quality clinical database. The participating cohorts and
this study were approved by local institutional review boards.
For this study, we included antiretroviral-naive, HIV-infected
patients starting ART at 1 of 5 participating CNICS sites con-
tributing comprehensive clinic visit data. All patients starting
ART between January 2000 and July 2010 who were alive 24
months following ART initiation were included. Because reten-
tion in care was calculated for the 24 months following ART
start, in accordance with the 24-month measurement period
for the DHHS retention core indicator [14], patients who
died prior to this date (n = 105) were excluded as they did not
have a complete observation measurement period. No other ex-
clusion criteria were used, and because retention was the prima-
ry independent variable under study, participants lost to care
within 24 months after ART initiation were not excluded or
censored; rather, this information was implicitly captured by
the retention measures under study.
Exposures and Outcomes
Retention in HIV medical care during a 24-month measure-
ment period following ART initiation was the principal expo-
sure of interest. Retention was calculated using 3 measures
including the IOM core indicator (based on the Health and Re-
sources Services Administration HIV/AIDS Bureau measure),
the DHHS core indicator, and a count of missed primary
HIV care clinic visits that were not canceled in advance by pa-
tient or provider (no-show visits). All retention measures were
calculated based on scheduled appointments with the primary
HIV care provider only, with subspecialty and urgent care visits
excluded. The IOM retention indicator is defined as 2 attended
visits separated by ≥90 days during a 12-month measurement
period [13]. For study purposes, achieving this indicator for
each of 2 consecutive 12-month periods following the ART
start date was used to define IOM retention at 24 months.
The DHHS core indicator is defined as at least 1 attended
visit in each 6-month period during a 24-month measurement
period, with ≥60 days between visits in adjacent 6-month
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periods [14]. Missed visits over the 24 months following ART
start were categorized as 0, 1–2, or >2 missed visits. For each
patient, a 24-month observation measurement period was de-
termined individually based on the ART start date. Attended
visits on the ART initiation date were not counted in the calcu-
lation of the IOM and DHHS core indicators, which included
scheduled visits subsequent to this date.
All-cause mortality, the principal outcome of interest, was as-
certained via query of the Social Security Death Index and/or
National Death Index. Because we used these national databas-
es, assessment of vital status as an outcome was not contingent
on participants remaining in care and under observation in the
clinical cohorts contributing to CNICS.
Statistical Analysis
Descriptive statistics including means, medians, frequencies,
and proportions were calculated and visual plots assessed to
evaluate the distribution of all study variables. Separate Cox
proportional hazards models assessed the relationships between
the 3 measures of retention at 24 months following ART start
(excluding patients who died within 24 months) and all-cause
mortality, with the origin for the time scale being 24 months
after ART initiation. Next, separate Cox proportional hazards
models assessed the independent association of missed clinic
visits with all-cause mortality among patients grouped by reten-
tion classification (retained vs not retained) at 24 months ac-
cording to the IOM and DHHS core indicators. Adjusted
models control for age at ART start, race, sex, baseline plasma
HIV RNA and CD4 count (date nearest ART start date within a
window of −180 to 14 days), and are stratified by site. We did
not adjust for time-updated CD4 count and plasma HIV RNA,
as these biomarkers are on the causal pathway between our pri-
mary exposure (retention in care) and outcome (all-cause mor-
tality). For all models, participants were censored on the date of
death or administratively in July 2012. All analyses were con-
ducted using SAS software, version 9.3.
RESULTS
Among 3672 study participants, the mean age was 38 years and
the majority were white (53%) and male (80%), with patients
starting ART with a baseline mean CD4 count and plasma
HIV RNA of 220 cells/µL and 4.9 log10 copies/mL, respectively
(Table 1). Participants were followed for a median of 6.0 years
(interquartile range, 3.8–8.7 years) from ART initiation. At
24 months following ART initiation, 64% and 59% of patients
met the IOM and DHHS retention core indicators, respectively,
with an average of 2.1 missed (no-show) visits accrued. Subse-
quently, 332 patients (9.0%) died during 16 102 person-years of
follow-up (20.6 deaths per 1000 person-years). Mortality rates
were lower among patients classified as retained by the IOM
Table 1. Characteristics of 3672 Antiretroviral-Naive HIV-
1–Infected Patients Initiating Combination Antiretroviral Therapy
at 5 CNICS Sites, 2000–2010
Characteristic No. (%) or Mean ± SD









Case Western Reserve University 405 (11)
University of Alabama at Birmingham 798 (22)
University of California, San Diego 876 (24)
University of North Carolina at Chapel Hill 723 (20)
University of Washington 870 (24)







Baselinea viral load, log10 copies/mL 4.9 ± 0.7
<10 000 453 (12)
10 000–100 000 1521 (41)
>100 000 1577 (43)
Missing/unknown 121 (3)
IOM retention core indicatorb at 24 mo
Retained 2358 (64)
Not retained 1314 (36)
DHHS retention core indicatorc at 24 mo
Retained 2166 (59)
Not retained 1506 (41)




Abbreviations: CNICS, Centers for AIDS Research Network of Integrated
Clinical Systems; DHHS, Department of Health and Human Services; HIV-1,
human immunodeficiency virus type 1; IOM, Institute of Medicine; SD,
standard deviation.
a Baseline defined as value nearest antiretroviral therapy (ART) start date within
a window of −180 to 14 days.
b IOM retention core indicator based on the Health and Resources Services
Administration HIV/AIDS Bureau measure, defined as 2 attended visits per
12-month period with >90 days between visits. Patients achieving this
measure in each of the 12-month periods following ART initiation were
classified as retained.
c DHHS retention core indicator defined as at least 1 attended visit in each 6-
month period during a 24-month measurement period, with ≥60 days between
visits in adjacent 6-month periods.
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indicator and DHHS indicator and with zero missed visits (16.0,
15.3, and 11.3 deaths per 1000 person-years, respectively) com-
pared with those classified as not retained or experiencing
missed clinic visits. In separate multivariable Cox proportional
hazards models, failure to achieve the IOM indicator (hazard
ratio [HR] = 2.23; 95% confidence interval [CI], 1.79–2.80;
29.5 deaths per 1000 person-years), failure to achieve the
DHHS indicator (HR = 2.36 [95% CI, 1.89–2.96], 29.0 deaths
per 1000 person-years), and missed clinic visits at 24 months
(1–2 no shows: HR = 1.98 [95% CI, 1.45–2.72], 20.4 deaths
per 1000 person-years; >2 no shows: HR = 3.20 [95% CI,
2.33–4.41], 30.9 deaths per 1000 person-years) were all associ-
ated with increased subsequent mortality (Table 2). Across all 3
models, older age, black race, and lower baseline CD4 count
Table 2. Separate Multivariable Cox Proportional Hazards Models Evaluating the Associations of Retention in Care Over the 24 Months
Following Antiretroviral Therapy (ART) Initiation According to 3 Retention Indicators With Subsequent Mortality Among 3672 HIV-








IOM retention core indicatora at 24 mo . . . . . .
Retained Referent
Not retained 2.23 (1.79–2.80)
DHHS retention core indicatorb at 24 mo . . . . . .
Retained Referent
Not retained 2.36 (1.89–2.96)




Age (per 10 y) 1.51 (1.36–1.68) 1.53 (1.37–1.70) 1.53 (1.37–1.70)
Race
White Referent Referent Referent
Black 1.72 (1.34–2.20) 1.70 (1.32–2.18) 1.48 (1.15–1.91)
Other/unknown 0.71 (.42–1.21) 0.72 (.42–1.22) 0.68 (.40–1.15)
Sex
Male Referent Referent Referent
Female 0.93 (.71–1.22) 0.94 (.72–1.23) 0.90 (.69–1.17)
Baselinec CD4 count, cells/µL
<50 2.61 (1.35–5.04) 2.59 (1.34–5.01) 2.37 (1.23–4.58)
50–199 1.93 (1.00–3.73) 1.88 (.97–3.63) 1.80 (.93–3.49)
200–349 1.18 (.60–2.31) 1.16 (.59–2.26) 1.17 (.60–2.28)
350–500 1.00 (.47–2.13) 0.97 (.46–2.06) 1.00 (.47–2.12)
>500 Referent Referent Referent
Missing/unknown 1.06 (.39–2.90) 1.02 (.37–2.80) 1.43 (.53–3.86)
Baselinec viral load, log10 copies/mL
<10 000 Referent Referent Referent
10 000–100 000 1.30 (.83–2.02) 1.34 (.86–2.08) 1.27 (.81–1.98)
>100 000 1.32 (.85–2.07) 1.37 (.88–2.15) 1.28 (.82–2.01)
Missing/unknown 1.77 (.88–3.56) 1.85 (.92–3.73) 1.81 (.91–3.59)
Multivariable models stratified by study site.
Abbreviations: CI, confidence interval; CNICS, Centers for AIDS Research Network of Integrated Clinical Systems; DHHS, Department of Health and Human
Services; HIV-1, human immunodeficiency virus type 1; HR, hazard ratio; IOM, Institute of Medicine.
a IOM retention core indicator based on the Health and Resources Services Administration HIV/AIDS Bureau measure, defined as 2 attended visits per 12-month
period with >90 days between visits. Patients achieving this measure in each of the 12-month periods following antiretroviral therapy (ART) initiation were classified
as retained.
b DHHS retention core indicator defined as at least 1 attended visit in each 6-month period during a 24-month measurement period, with ≥60 days between visits in
adjacent 6-month periods.
c Baseline defined as value nearest ART start date within a window of −180 to 14 days.
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were consistently associated with increased mortality. Notably,
the distribution of all 3 retention measures were fairly consis-
tent in analyses stratified by year of ART initiation, with no
clear temporal trends observed. Similarly, the relationship be-
tween each retention measure and all-cause mortality remained
relatively stable over time during the study period (data not
shown).
Among patients classified as retained at 24 months by the
IOM (n = 2358) and DHHS (n = 2166) retention core indica-
tors, missed visits were common, with roughly two-thirds of
persons having at least 1 no-show visit, and one-quarter of pa-
tients missing >2 visits over this interval (Table 3). Separate
multivariable Cox proportional hazards models restricted to pa-
tients classified as retained by the IOM and DHHS retention
core indicators demonstrated increased mortality risk among
patients accruing more missed clinic visits over the 24 months
following ART initiation (IOM: 1–2 no shows, HR = 1.78 [95%
CI, 1.17–2.70], 15.3 deaths per 1000 person-years; >2 no shows:
HR = 3.61 [95% CI, 2.35–5.55], 24.9 deaths per 1000 person-
years; and DHHS: 1–2 no shows, HR = 1.71 [95% CI, 1.10–
2.65], 14.4 deaths per 1000 person-years; >2 no shows:
HR = 3.62 [95% CI, 2.30–5.68], 23.8 deaths per 1000 person-
years; Tables 3 and 4, Figure 1).
Missed visits were more common among patients classified
as not retained at 24 months by the IOM (n = 1314) and
DHHS (n = 1506) retention core indicators compared with
those classified as retained, although roughly a quarter of “not
retained” patients had zero no-show visits (Table 3). Separate
multivariable Cox proportional hazards models restricted to pa-
tients classified as not retained by the core indicators demon-
strated increased mortality risk among patients accruing more
missed clinic visits over the 24 months following ART initiation
(IOM: 1–2 no shows, HR = 1.63 [95% CI, .98–2.72], 28.5 deaths
per 1000 person-years; >2 no shows: HR = 2.11 [95% CI, 1.26–
3.51], 40.7 deaths per 1000 person-years; and DHHS: 1–2 no
shows, HR = 1.76 [95% CI, 1.08–2.85], 28.2 deaths per 1000
person-years; >2 no shows: HR = 2.32 [95% CI, 1.43–3.77]
39.8 deaths per 1000 person-years; Tables 3 and 5, Figure 1).
Moreover, whereas increased mortality rates were observed
overall among patients classified as not retained by core indica-
tors, and clear dose-response relationships were observed with
increasing missed visits within retention categories, interesting
relationships were observed when comparing mortality rates
across retention categories (Table 3). For example, patients clas-
sified as retained by either core indicator who accrued 1–2
missed visits during the 24 months following ART initiation
had mortality rates comparable to those classified as not re-
tained and who had zero missed visits (Table 3).
DISCUSSION
These data are among the first to provide empirical validation of
the IOM and DHHS core indicators of retention in care with
definitive clinical outcomes. When measured over the 24
months following ART initiation, failure to achieve these reten-
tion core indicators was strongly associated with subsequent
all-cause mortality. However, study findings indicate that as-
sessment of missed (no-show) clinic visits, in conjunction
with these core indicators, provides additional, independent
prognostic value. Among patients grouped by retention in
care classification (retained vs not retained) by the IOM and
DHHS retention core indicators, missed visits were exceedingly
common and were associated with a substantially elevated mor-
tality risk. Accordingly, caution is warranted in relying solely
Table 3. Frequency of Missed Clinic Visits and Mortality Rates (Deaths per 1000 Person-Years of Follow-Up) Among Patients Classified as
Retained and Not Retained at 24 Months Following Antiretroviral Therapy Initiation According to Institute of Medicine and Department of
Health and Human Services Core Indicators at 5 CNICS Sites, 2000–2010
Characteristic
Retained at 24 Months by
IOM Core Indicatora
(n = 2358)
Not Retained at 24 Months by
IOM Core Indicatora
(n = 1314)
Retained at 24 Months by
DHHS Core Indicatorb
(n = 2166)
Not Retained at 24 Months by
DHHS Core Indicatorb
(n = 1506)
Missed (no-show) visits at 24 mo
0 861 (37%); 9.9 314 (24%); 15.4 827 (38%); 9.8 348 (23%); 15.0
1–2 848 (36%); 15.3 566 (43%); 28.5 766 (35%); 14.4 648 (43%); 28.2
>2 649 (28%); 24.9 434 (33%); 40.7 573 (26%); 23.8 510 (34%); 39.8
Data are presented as No. (%); deaths per 1000 person-years of follow-up.
Abbreviations: CNICS, Centers for AIDS Research Network of Integrated Clinical Systems; DHHS, Department of Health and Human Services; IOM, Institute of
Medicine.
a IOM retention core indicator based upon the Health and Resources Services Administration HIV/AIDS Bureau measure, defined as 2 attended visits per 12-month
period with >90 days between visits. Patients achieving this measure in each of the 12-month periods following antiretroviral therapy initiation were classified as
retained.
b DHHS retention core indicator defined as at least 1 attended visit in each 6-month period during a 24-month measurement period, with ≥60 days between visits in
adjacent 6-month periods.
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on retention core indicators for HIV policy, clinical, and pro-
grammatic purposes. Although these measures have clear
value, considerable additional prognostic information is provid-
ed, for both patients classified as retained and not retained, by
further evaluating missed clinic visits, a readily available and
immediately actionable clinical marker.
The HIV care continuum and retention in care are at the
forefront of the domestic HIV policy, public health, and clinical
agenda, with enhanced emphasis garnered by the recently re-
leased HIV Care Continuum Initiative, which magnifies the
focus of the US National HIV/AIDS Strategy on this pivotal
area [11, 12]. In response to these initiatives from the federal
government, the IOM and DHHS have released clinical core in-
dicators [13, 14], including measures for retention in care,
which are being widely implemented with required reporting
on these measures for agencies receiving federal funding for
the provision of HIV services. Implementation and adoption
of these core indicators are important to assess progress toward
local and national goals, and to standardize assessment and
comparison across settings, but there is a potential shortcoming
in using these indicators alone to define HIV care retention.
Our findings suggest that the additional inclusion of missed
clinic visits in HIV policy, clinical, and public health planning
is prudent to optimize classification, risk stratification, and re-
source allocation to those in greatest need. Agencies with access
to missed clinic visits should be encouraged to take advantage of
these additional data, as our findings demonstrate their value.
In recent years a number of approaches to measuring reten-
tion in care have emerged, each with strengths and limitations,
and with no clear gold standard established [16]. Broadly speak-
ing, retention measures include those based solely on attended
clinic visits (eg, the IOM and DHHS core indicators) and others
that account for missed clinic visits. Prior research has shown
that both types of measures predict mortality among patients
newly entering HIV care or initiating ART [19–21]. A novel
contribution of this study is the concomitant use of a measure
from each broad category, rather than using them in isolation,
as has typically been the approach to date. This observation sup-
ports recent research suggesting that measures based on attend-
ed and missed visits may be tapping into different aspects of
retention [16], and that there is complementary value in
using measures in combination.
Recent guidelines have recommended systematic monitoring
of linkage and retention in HIV care for all persons living with
HIV infection [15]. It has been noted that a number of data sys-
tems are available to monitor HIV care engagement including
public health surveillance, administrative claims, and clinic-
based utilization databases. As for retention measures, each
monitoring system has distinct advantages and limitations,
and integration of systems has been shown to enhance correct
classification of HIV care engagement [15]. In recent years there
has been a dramatic shift in paradigm, with the use of CD4
counts and plasma HIV RNA laboratory tests reported to public
health surveillance being used as a proxy for care visits to mon-
itor HIV care engagement and to inform interventions for
Table 4. Separate Cox Proportional Hazards Models Evaluating
the Association of Missed Clinic Visits With Long-Term Mortality
Among Patients Classified as Retained at 24 Months Following
Antiretroviral Therapy Initiation According to Institute of Medicine











Indicatorb (n = 2166),
HR (95% CI)
Missed (no-show) visits at 24 mo
0 Referent Referent
1–2 1.78 (1.17–2.70) 1.71 (1.10–2.65)
>2 3.61 (2.35–5.55) 3.62 (2.30–5.68)
Age (per 10 y) 1.66 (1.42–1.94) 1.63 (1.38–1.92)
Race
White Referent Referent
Black 1.14 (.80–1.61) 1.15 (.80–1.66)
Other/unknown 0.65 (.31–1.36) 0.65 (.29–1.43)
Sex
Male Referent Referent
Female 0.69 (.46–1.03) 0.75 (.50–1.14)
Baselinec CD4 count, cells/µL
<50 1.80 (.76–4.24) 1.49 (.63–3.53)
50–199 1.38 (.58–3.24) 1.23 (.52–2.91)
200–349 0.93 (.38–2.23) 0.78 (.32–1.91)
350–500 0.92 (.34–2.47) 0.92 (.34–2.48)
>500 Referent Referent
Missing/unknown 3.31 (.95–11.57) 2.44 (.59–10.13)
Baselinec viral load, log10 copies/mL
<10 000 Referent Referent
10 000–100 000 1.00 (.58–1.75) 0.96 (.53–1.73)
>100 000 0.78 (.44–1.37) 0.71 (.39–1.29)
Missing/unknown 1.62 (.69–3.77) 1.42 (.57–3.52)
Multivariable models stratified by study site.
Abbreviations: CI, confidence interval; CNICS, Centers for AIDS Research
Network of Integrated Clinical Systems; DHHS, Department of Health and
Human Services; HR, hazard ratio; IOM, Institute of Medicine.
a IOM retention core indicator based upon the Health and Resources Services
Administration HIV/AIDS Bureau measure, defined as 2 attended visits per 12-
month period with >90 days between visits. Patients achieving this measure in
each of the 12-month periods following antiretroviral therapy (ART) initiation
were classified as retained.
b DHHS retention core indicator defined as at least 1 attended visit in each 6-
month period during a 24-month measurement period, with ≥60 days between
visits in adjacent 6-month periods.
c Baseline defined as value nearest ART start date within a window of −180 to
14 days.
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persons identified as out of care [22]. Notably, laboratory sur-
veillance data can be used to calculate retention measures
only, as they are a proxy for attended visits, and missed clinic
visits are not reported to public health agencies including
the Centers for Disease Control and Prevention. Importantly,
surveillance allows for improved classification of retention sta-
tus of persons who have transferred from one clinic to another,
which may not be captured at the clinic level. However, infor-
mation about missed clinic visits are uniquely available through
administrative, billing, or clinical data systems at the clinic level.
Accordingly, our findings are germane to HIV clinic directors,
providers, and staff. The added value of missed clinic visits for
identifying patients at increased mortality risk can help guide
allocation of limited resources to those who may derive the
greatest benefits. For example, cost- and time-intensive peer
mentor, patient navigation, and intensive case management
programs are among the few evidence-based approaches to en-
hancing HIV care engagement [15, 23]. Such programs could be
targeted to those with missed clinic visits—even among patients
considered retained according to the IOM and DHHS core in-
dicators, as resources allow. Moreover, integration of surveil-
lance and clinic-based data systems to comprehensively
capture retention in a given geographical area affords the op-
portunity to improve classification of HIV care engagement.
Such integrated approaches could capitalize upon the strengths
and overcome the limitations of each data system and allow for
retention in care programs that leverage the unique information
provided by measures based on attended and missed clinic vis-
its, captured by public health departments and clinics,
respectively.
Figure 1. Kaplan–Meier survival curves for all-cause mortality among patients classified as retained and not retained at 24 months following antiretro-
viral therapy initiation according to the Institute of Medicine (IOM) (A and B ) and Department of Health and Human Services (DHHS) (C and D ) core in-
dicators stratified by missed (no-show) clinic visits. A, Retained at 24 months according to IOM core indicator (n = 2358). B, Not retained at 24 months
according to IOM core indicator (n = 1314). C, Retained at 24 months according to DHHS core indicator (n = 2166). D, Not retained at 24 months according to
DHHS core indicator (n = 1506). Abbreviation: ART, antiretroviral therapy.
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Our study has limitations. Findings may not generalize to
other settings, although we note the geographic diversity of
study sites within the United States. As an observational
study, we can identify associations but cannot attribute causal-
ity. We measure retention over a relatively short observation
period of 24 months. Although longer-term retention over de-
cades of treatment is the current paradigm of HIV manage-
ment, discrete measurement over shorter time periods as
evaluated here is highly actionable in terms of risk stratification
for programmatic purposes. Additional studies are ongoing
within CNICS to evaluate the impact of retention over longer
measurement periods on health outcomes. There is potential
for misclassification of study variables, but this is believed to
be minimal based on the CNICS data quality systems and use
of national vital status databases.
In conclusion, our study contributes novel findings germane
to the HIV care continuum, with implications for the policy,
clinical, and population health communities. The additional as-
sessment of missed clinic visits in conjunction with the IOM
and DHHS HIV retention in care core indicators meaningfully
enhanced prognostic value for all-cause mortality among pa-
tients initiating ART. Accordingly, caution is warranted in rely-
ing solely on core indicators to define retention in care and to
inform local, state, and national programmatic planning.
Missed clinic visits are an important indicator with indepen-
dent value that can be used along with core indicators to
guide allocation of limited resources in an effort to optimize in-
dividual- and population-level health outcomes.
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